 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Amarillo Biosciences, Inc.
 |
Amarillo Biosciences, Inc. |
 |
 |
 |
PROFILE |
 |
Amarillo: home to cattlemen, prairies, and interferon? Development-stage Amarillo Biosciences hopes its interferon alpha (IFNa), which modulates the immune system, will help those suffering from a range of maladies, including hepatitis, fibromyalgia (chronic stiffness of the joints), and Sjogren's syndrome, a condition that leaves tissues painfully dry. The FDA has granted orphan drug status to IFNa to treat Behcet's disease, the chronic inflammation of blood vessels. Japanese firm Hayashibara Biochemical Laboratories, Amarillo Biosciences' primary development partner, owns nearly 45% of the company.
COMPETITION |
 |
Biogen, Inc. (BGEN)
Genentech, Inc. (DNA)
Interferon Sciences, Inc. (IFSC)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.10
Employees: 7
Revenue per employee: $14,285.71
KEY PEOPLE |
 |
Joseph M. Cummins
CEO
Joseph M. Cummins
CFO
CONTACT INFO |
 |
800 W. 9th Ave.
Amarillo, TX 79101
US
Phone: 806-376-1741
Fax: 806-376-9301
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |